What question did this study set out to answer?

To emphasize the significance of diagnosing giant cell arteritis (GCA) in patients on pembrolizumab who present with headaches.

April 3, 2026Open Access

Ver artículo completo

Giant Cell Arteritis as a Form of Pembrolizumab-Associated Vascular Toxicity

Puntos clave

To emphasize the significance of diagnosing giant cell arteritis (GCA) in patients on pembrolizumab who present with headaches.
Case presentation of a patient receiving pembrolizumab
Evaluation of symptoms including new headache
Consideration of differential diagnoses
Monitoring of treatment side effects
Identification of GCA in the patient post-treatment with pembrolizumab
Acknowledgment of headache as a potential symptom of vascular toxicity
Highlight of the necessity for clinicians to consider GCA in similar cases

Resumen

This case highlights the importance of considering GCA as a possible diagnosis in patients receiving immune checkpoint inhibitors therapy who report development of new headache.

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo

Cite This Study

Umemoto et al. (Wed,) studied this question.

synapsesocial.com/papers/69cf5d4e5a333a821460afac https://doi.org/https://doi.org/10.1016/j.jaccas.2026.107742

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

Preguntar a la IA

Me gusta

Guardar

Ver artículo completo